With Medtronic, Microchip, imec, Tyndall, Argotech, the Universiteit Gent, Politecnico di Torino, INSERM and the Universiteit Maastricht, InSiDe is partnering European leaders in respectively medical devices, micro-electronics, silicon photonics and arterial biomechanics. InSiDe will help to secure their leadership by developing a new application that advances the existing background. In this collaboration, the partners will be sharing their experience and background for the purpose of creating a state-of-the-art CVD screening device that they would not be able to develop alone and in the same timeframe.
The possibility for earlier detection of risk for CVD makes it possible to start earlier treatment. In these early stages of the disease this could be achieved simply by a change in lifestyle and/or relatively cheap cholesterol lowering drugs such as statins. Thus, more complicated treatments, like stenting and ultimately cerebral and myocardial infarction may be prevented.
InSiDe will enable Medtronic to access a new market segment, Hypertension Management and extend its Diagnostics business, currently focused on Insertable Cardiac Monitors. Microchip has a well-established customer base in medical electronics, particularly in cardiac management, electro-stimulation and robotics as well as high speed communication modules. The Diagnostics market is however an area that Microchip is not currently strongly involved in and therefore offers a new revenue and product stream.
The new knowledge and expertise developed by imec, UGent and Tyndall in InSiDe will be made available to EU companies in the medical diagnostics market and other markets. It will be used to bring integrated photonics to the next level, for use in all kind of applications. It is the mission of these institutions to transfer technology to industrial partners so as to create an economical and societal impact with the developed technology.
Further information can be found on the InSiDe public website (www.inside-h2020.eu).
